{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T13:10:25Z","timestamp":1789564225780,"version":"build-2803163510"},"reference-count":43,"publisher":"Harborside Press, LLC","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:p>The treatment of early-stage Hodgkin lymphoma is one of oncology\u2019s great success stories. Numerous large randomized trials have tested and refined conventional chemotherapy regimens, optimized radiation therapy (RT) approaches, explored the integration of metabolic imaging such as PET\/CT, and are now evaluating novel agents. What was once a fatal disease is now cured in almost all patients. Combined-modality therapy, typically involving a short course of chemotherapy followed by low-dose, highly conformal RT, has emerged as the most effective strategy for achieving durable remissions. Nonetheless, concerns about the long-term toxicities associated with RT have prompted investigations into chemotherapy-only regimens as a potential alternative to combined-modality therapy. To date, neither interim nor postchemotherapy PET\/CT imaging has been able to identify patients who can safely omit consolidation RT without compromising efficacy, although additional studies are ongoing. Meanwhile, novel agents such as nivolumab and brentuximab vedotin have significantly advanced the treatment of advanced-stage disease and are now demonstrating promising activity in early-stage Hodgkin lymphoma. In parallel with advances in systemic therapy, radiation technologies have also progressed substantially. Techniques such as proton therapy, intensity-modulated RT, and image-guided RT dramatically reduce radiation exposure to healthy tissues compared with historical approaches, thereby improving the therapeutic ratio. Despite the high cure rates achieved today, clinical trials continue to explore novel and personalized approaches to achieve long-term remission without compromising quality of life.<\/jats:p>","DOI":"10.6004\/jnccn.2026.7019","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T12:53:08Z","timestamp":1789563188000},"source":"Crossref","is-referenced-by-count":0,"title":["Controversies in the Management of Early-Stage Hodgkin Lymphoma: The Role of Radiation Therapy"],"prefix":"10.6004","volume":"24","author":[{"given":"Yorleny","family":"Vicioso Mora","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Duke University Medical Center, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"Kelsey","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Duke University Medical Center, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","series-title":"J Clin Oncol","first-page":"2835","article-title":"Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group","volume":"37","author":"Fuchs M","year":"2019","unstructured":"Fuchs M, Goergen H, Kobe C,  Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group. J Clin Oncol 2019;37:2835\u20132845."},{"key":"B2","series-title":"N Engl J Med","first-page":"1598","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin\u2019s lymphoma","volume":"372","author":"Radford J","year":"2015","unstructured":"Radford J, Illidge T, Counsell N,  Results of a trial of PET-directed therapy for early-stage Hodgkin\u2019s lymphoma. N Engl J Med 2015;372:1598\u20131607."},{"key":"B3","series-title":"J Clin Oncol","first-page":"1786","article-title":"Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"35","author":"Marc PE","year":"2017","unstructured":"Marc PE, Girinsky T, Federico M,  Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 trial. J Clin Oncol 2017;35:1786\u20131794."},{"key":"B4","series-title":"N Engl J Med","first-page":"399","article-title":"ABVD alone versus radiation-based therapy in limited-stage Hodgkins lymphoma","volume":"366","author":"Meyer RM","year":"2012","unstructured":"Meyer RM, Gospodarowicz MK, Connors JM,  ABVD alone versus radiation-based therapy in limited-stage Hodgkins lymphoma. N Engl J Med 2012;366:399\u2013408."},{"key":"B5","series-title":"J Natl Cancer Inst","first-page":"1466","article-title":"Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage I-II Hodgkins disease","volume":"80","author":"Pavlovsky S","year":"1988","unstructured":"Pavlovsky S, Maschio M, Santarelli MT,  Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage I-II Hodgkins disease. J Natl Cancer Inst 1988;80:1466\u20131473."},{"key":"B6","series-title":"J Clin Oncol","first-page":"3174","article-title":"Long-term results of CCG 5942: a randomized comparison of chemotherapy with and without radiotherapy for children with Hodgkin\u2019s lymphoma\u2014a report from the Children\u2019s Oncology Group","volume":"30","author":"Wolden SL","year":"2012","unstructured":"Wolden SL, Chen L, Kelly KM,  Long-term results of CCG 5942: a randomized comparison of chemotherapy with and without radiotherapy for children with Hodgkin\u2019s lymphoma\u2014a report from the Children\u2019s Oncology Group. J Clin Oncol 2012;30:3174\u20133180."},{"key":"B7","series-title":"Leuk Lymphoma","first-page":"1721","article-title":"Randomized comparison of consolidation radiation versus observation in bulky Hodgkin\u2019s lymphoma with post-chemotherapy negative positron emission tomography scans","volume":"48","author":"Picardi M","year":"2007","unstructured":"Picardi M, De Renzo A, Pane F,  Randomized comparison of consolidation radiation versus observation in bulky Hodgkin\u2019s lymphoma with post-chemotherapy negative positron emission tomography scans. Leuk Lymphoma 2007;48:1721\u20131727."},{"key":"B8","series-title":"Blood","first-page":"3483","article-title":"Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease","volume":"104","author":"Straus DJ","year":"2004","unstructured":"Straus DJ, Portlock CS, Qin J,  Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood 2004;104:3483\u20133489."},{"key":"B9","series-title":"J Clin Oncol","first-page":"62","article-title":"Consolidation radiation after complete remission in Hodgkin\u2019s disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need?","volume":"22","author":"Laskar S","year":"2004","unstructured":"Laskar S, Gupta T, Vimal S,  Consolidation radiation after complete remission in Hodgkin\u2019s disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need? J Clin Oncol 2004;22:62\u201368."},{"key":"B10","series-title":"J Clin Oncol","first-page":"Abstract 6505","article-title":"First results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin\u2019s lymphoma (HL)","volume":"23(Suppl)","author":"Noordijk EM","year":"2005","unstructured":"Noordijk EM, Thomas J, Ferme C,  First results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin\u2019s lymphoma (HL). J Clin Oncol 2005;23(Suppl):Abstract 6505."},{"key":"B11","series-title":"J Clin Oncol","first-page":"3601","article-title":"Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin\u2019s lymphoma: results of the HD8 trial of the German Hodgkin\u2019s Lymphoma Study Group","volume":"21","author":"Engert A","year":"2003","unstructured":"Engert A, Schiller P, Josting A,  Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin\u2019s lymphoma: results of the HD8 trial of the German Hodgkin\u2019s Lymphoma Study Group. J Clin Oncol 2003;21:3601\u20133608."},{"key":"B12","series-title":"J Clin Oncol","first-page":"2435","article-title":"Second solid tumors in patients with Hodgkin\u2019s disease cured after radiation or chemotherapy plus adjuvant low-dose radiation","volume":"14","author":"Salloum E","year":"1996","unstructured":"Salloum E, Doria R, Schubert W,  Second solid tumors in patients with Hodgkin\u2019s disease cured after radiation or chemotherapy plus adjuvant low-dose radiation. J Clin Oncol 1996;14:2435\u20132443."},{"key":"B13","series-title":"J Clin Oncol","first-page":"2835","article-title":"ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin\u2019s disease: long-term results","volume":"22","author":"Bonadonna G","year":"2004","unstructured":"Bonadonna G, Bonfante V, Viviani S,  ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin\u2019s disease: long-term results. J Clin Oncol 2004;22:2835\u20132841."},{"key":"B14","series-title":"Clin Oncol (R Coll Radiol)","first-page":"47","article-title":"Long-term results of a randomised trial of involved field radiotherapy vs extended field radiotherapy in stage I and II Hodgkin lymphoma","volume":"17","author":"Hoskin PJ","year":"2005","unstructured":"Hoskin PJ, Smith P, Maughan TS,  Long-term results of a randomised trial of involved field radiotherapy vs extended field radiotherapy in stage I and II Hodgkin lymphoma. Clin Oncol (R Coll Radiol) 2005;17:47\u201353."},{"key":"B15","series-title":"J Clin Oncol","first-page":"605","article-title":"Combined-modality therapy versus radiotherapy alone for treatment of early-stage Hodgkin\u2019s disease: cure balanced against complications","volume":"24","author":"Koontz BF","year":"2006","unstructured":"Koontz BF, Kirkpatrick JP, Clough RW,  Combined-modality therapy versus radiotherapy alone for treatment of early-stage Hodgkin\u2019s disease: cure balanced against complications. J Clin Oncol 2006;24:605\u2013611."},{"key":"B16","series-title":"J Clin Oncol","first-page":"1489","article-title":"Long-term solid cancer risk among 5-year survivors of Hodgkin\u2019s lymphoma","volume":"25","author":"Hodgson DC","year":"2007","unstructured":"Hodgson DC, Gilbert ES, Dores GM,  Long-term solid cancer risk among 5-year survivors of Hodgkin\u2019s lymphoma. J Clin Oncol 2007;25:1489\u20131497."},{"key":"B17","series-title":"Ann Oncol","first-page":"2953","article-title":"Comparing long-term toxicity and efficacy of combined modality treatment including extended- or involved-field radiotherapy in early-stage Hodgkin\u2019s lymphoma","volume":"23","author":"Sasse S","year":"2012","unstructured":"Sasse S, Klimm B, G\u00f6rgen H,  Comparing long-term toxicity and efficacy of combined modality treatment including extended- or involved-field radiotherapy in early-stage Hodgkin\u2019s lymphoma. Ann Oncol 2012;23:2953\u20132959."},{"key":"B18","series-title":"Int J Radiat Oncol Biol Phys","first-page":"35","article-title":"Secondary breast cancer risk by radiation volume in women with Hodgkin lymphoma","volume":"97","author":"Conway JL","year":"2017","unstructured":"Conway JL, Connors JM, Tyldesley S,  Secondary breast cancer risk by radiation volume in women with Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 2017;97:35\u201341."},{"key":"B19","series-title":"Clin Transl Radiat Oncol","first-page":"64","article-title":"Second malignancies in patients with Hodgkin\u2019s lymphoma: half a century of experience","volume":"35","author":"Shbib Dabaja B","year":"2022","unstructured":"Shbib Dabaja B, Boyce-Fappiano D, Dong W,  Second malignancies in patients with Hodgkin\u2019s lymphoma: half a century of experience. Clin Transl Radiat Oncol 2022;35:64\u201369."},{"key":"B20","series-title":"Blood","first-page":"2257","article-title":"Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines","volume":"129","author":"Van Nimwegen FA","year":"2017","unstructured":"Van Nimwegen FA, Ntentas G, Darby SC,  Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines. Blood 2017;129:2257\u20132265."},{"key":"B21","series-title":"Blood","first-page":"1878","article-title":"Late cardiotoxicity after treatment for Hodgkin lymphoma","volume":"109","author":"Aleman BM","year":"2007","unstructured":"Aleman BM, van den Belt-Dusebout AW, De Bruin ML,  Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 2007;109:1878\u20131886."},{"key":"B22","series-title":"JAMA","first-page":"1949","article-title":"Factors affecting late mortality from heart disease after treatment of Hodgkin\u2019s disease","volume":"270","author":"Hancock SL","year":"1993","unstructured":"Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin\u2019s disease. JAMA 1993;270:1949\u20131955."},{"key":"B23","series-title":"Pediatr Blood Cancer","first-page":"1145","article-title":"Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for Hodgkin disease in children and adolescents: report from the longitudinal GPOH follow-up project of the German-Austrian DAL-HD studies","volume":"55","author":"Schellong G","year":"2010","unstructured":"Schellong G, Riepenhausen M, Bruch C,  Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for Hodgkin disease in children and adolescents: report from the longitudinal GPOH follow-up project of the German-Austrian DAL-HD studies. Pediatr Blood Cancer 2010;55:1145\u20131152."},{"key":"B24","series-title":"J Clin Oncol","first-page":"1193","article-title":"Nivolumab and doxorubicin, vinblastine, and dacarbazine in early-stage unfavorable Hodgkin lymphoma: final analysis of the randomized German Hodgkin Study Group phase II NIVAHL trial","volume":"41","author":"Br\u00f6ckelmann PJ","year":"2023","unstructured":"Br\u00f6ckelmann PJ, B\u00fchnen I, Meissner J,  Nivolumab and doxorubicin, vinblastine, and dacarbazine in early-stage unfavorable Hodgkin lymphoma: final analysis of the randomized German Hodgkin Study Group phase II NIVAHL trial. J Clin Oncol 2023;41:1193\u20131199."},{"key":"B25","series-title":"J Clin Oncol","first-page":"327","article-title":"Brentuximab vedotin plus AVD for first-line treatment of early-stage unfavorable Hodgkin lymphoma (BREACH): a multicenter, open-label, randomized, phase II trial","volume":"41","author":"Fornecker LM","year":"2023","unstructured":"Fornecker LM, Lazarovici J, Aurer I,  Brentuximab vedotin plus AVD for first-line treatment of early-stage unfavorable Hodgkin lymphoma (BREACH): a multicenter, open-label, randomized, phase II trial. J Clin Oncol 2023;41:327\u2013335."},{"key":"B26","series-title":"N Engl J Med","first-page":"640","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin\u2019s lymphoma","volume":"363","author":"Engert A","year":"2010","unstructured":"Engert A, Pl\u00fctschow A, Eich HT,  Reduced treatment intensity in patients with early-stage Hodgkin\u2019s lymphoma. N Engl J Med 2010;363:640\u2013652."},{"key":"B27","series-title":"Lancet Oncol","first-page":"223","article-title":"PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Borchmann P","year":"2021","unstructured":"Borchmann P, Pl\u00fctschow A, Kobe C,  PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2021;22:223\u2013234."},{"key":"B28","series-title":"J Clin Oncol","first-page":"19","article-title":"Long-term follow-up of the response-adapted intergroup EORTC\/LYSA\/FIL H10 trial for localized Hodgkin lymphoma","volume":"42","author":"Federico M","year":"2024","unstructured":"Federico M, Fortpied C, Stepanishyna Y,  Long-term follow-up of the response-adapted intergroup EORTC\/LYSA\/FIL H10 trial for localized Hodgkin lymphoma. J Clin Oncol 2024;42:19\u201325."},{"key":"B29","series-title":"Blood","first-page":"1013","article-title":"CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET","volume":"132","author":"Straus DJ","year":"2018","unstructured":"Straus DJ, Jung SH, Pitcher B,  CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. Blood 2018;132:1013\u20131021."},{"key":"B30","series-title":"J Clin Oncol","first-page":"1023","article-title":"Positron emission tomography-adapted therapy in bulky stage I\/II classic Hodgkin lymphoma: CALGB 50801 (Alliance)","volume":"41","author":"LaCasce AS","year":"2023","unstructured":"LaCasce AS, Dockter T, Ruppert AS,  Positron emission tomography-adapted therapy in bulky stage I\/II classic Hodgkin lymphoma: CALGB 50801 (Alliance). J Clin Oncol 2023;41:1023\u20131034."},{"key":"B31","series-title":"J Clin Oncol","first-page":"4096","article-title":"Second cancer risk after chemotherapy for Hodgkin\u2019s lymphoma: a collaborative British cohort study","volume":"29","author":"Swerdlow AJ","year":"2011","unstructured":"Swerdlow AJ, Higgins CD, Smith P,  Second cancer risk after chemotherapy for Hodgkin\u2019s lymphoma: a collaborative British cohort study. J Clin Oncol 2011;29:4096\u20134104."},{"key":"B32","series-title":"Cancer","first-page":"850","article-title":"Prevalence of anthracycline- related cardiac dysfunction in long-term survivors of adult-onset lymphoma","volume":"124","author":"Armenian SH","year":"2018","unstructured":"Armenian SH, Mertens L, Slorach C,  Prevalence of anthracycline- related cardiac dysfunction in long-term survivors of adult-onset lymphoma. Cancer 2018;124:850\u2013857."},{"key":"B33","series-title":"J Clin Oncol","first-page":"1903","article-title":"Doxorubicin exposure and breast cancer risk in survivors of adolescent and adult Hodgkin lymphoma","volume":"42","author":"Neppelenbroek SIM","year":"2024","unstructured":"Neppelenbroek SIM, Geurts YM, Aleman BMP,  Doxorubicin exposure and breast cancer risk in survivors of adolescent and adult Hodgkin lymphoma. J Clin Oncol 2024;42:1903\u20131913."},{"key":"B34","series-title":"Radiation Oncology","first-page":"62","article-title":"Fondazione Italiana Linfomi (FIL) expert consensus on the use of intensity-modulated and image-guided radiotherapy for Hodgkin\u2019s lymphoma involving the mediastinum","volume":"15","author":"Filippi Alessandro R","year":"2020","unstructured":"Filippi Alessandro R, Meregalli S, Di Russo A,  Fondazione Italiana Linfomi (FIL) expert consensus on the use of intensity-modulated and image-guided radiotherapy for Hodgkin\u2019s lymphoma involving the mediastinum. Radiation Oncology 2020;15:62."},{"key":"B35","series-title":"Int J Radiat Oncol Biol Phys","first-page":"1522","article-title":"Dosimetric benefits of intensity-modulated radiotherapy combined with the deep-inspiration breath-hold technique in patients with mediastinal Hodgkin\u2019s lymphoma","volume":"82","author":"Paumier A","year":"2012","unstructured":"Paumier A, Ghalibafian M, Gilmore J,  Dosimetric benefits of intensity-modulated radiotherapy combined with the deep-inspiration breath-hold technique in patients with mediastinal Hodgkin\u2019s lymphoma. Int J Radiat Oncol Biol Phys 2012;82:1522\u20131527."},{"key":"B36","series-title":"Cancers (Basel)","first-page":"690","article-title":"Dosimetric impact of voluntary deep inspiration breath hold (DIBH) in mediastinal Hodgkin lymphomas: a comparative evaluation of three different intensity modulated radiation therapy (IMRT) delivery methods using voluntary DIBH and free breathing techniques","volume":"16","author":"Mohanty S","year":"2024","unstructured":"Mohanty S, Joshi K, Gamre P,  Dosimetric impact of voluntary deep inspiration breath hold (DIBH) in mediastinal Hodgkin lymphomas: a comparative evaluation of three different intensity modulated radiation therapy (IMRT) delivery methods using voluntary DIBH and free breathing techniques. Cancers (Basel) 2024;16:690."},{"key":"B37","series-title":"Int J Radiat Oncol Biol Phys","first-page":"449","article-title":"Effective dose reduction to cardiac structures using protons compared with 3DCRT and IMRT in mediastinal Hodgkin lymphoma","volume":"84","author":"Hoppe BS","year":"2012","unstructured":"Hoppe BS, Flampouri S, Su Z,  Effective dose reduction to cardiac structures using protons compared with 3DCRT and IMRT in mediastinal Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 2012;84:449\u2013455."},{"key":"B38","series-title":"Cancer Radioth\u00e9rapie","first-page":"922","article-title":"Proton therapy versus best photon for mediastinal Hodgkin lymphoma: dosimetry comparison and treatment using ILROG guidelines","volume":"23","author":"Abbassi LM","year":"2019","unstructured":"Abbassi LM, Goudjil F, Ars\u00e8ne-Henry A,  Proton therapy versus best photon for mediastinal Hodgkin lymphoma: dosimetry comparison and treatment using ILROG guidelines. Cancer Radioth\u00e9rapie 2019;23:922\u2013925."},{"key":"B39","series-title":"J Clin Oncol","first-page":"2266","article-title":"Impact of risk-adapted therapy for pediatric Hodgkin lymphoma on risk of long-term morbidity: a report from the Childhood Cancer Survivor Study","volume":"39","author":"Oeffinger KC","year":"2021","unstructured":"Oeffinger KC, Stratton KL, Hudson MM,  Impact of risk-adapted therapy for pediatric Hodgkin lymphoma on risk of long-term morbidity: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2021;39:2266\u20132275."},{"key":"B40","series-title":"BMJ","first-page":"l6794","article-title":"Major cardiac events for adult survivors of childhood cancer diagnosed between 1970 and 1999: report from the Childhood Cancer Survivor Study cohort","volume":"368","author":"Mulrooney DA","year":"2020","unstructured":"Mulrooney DA, Hyun G, Ness KK,  Major cardiac events for adult survivors of childhood cancer diagnosed between 1970 and 1999: report from the Childhood Cancer Survivor Study cohort. BMJ 2020;368:l6794."},{"key":"B41","article-title":"NCCN Clinical Practice Guidelines in Oncology: Hodgkin Lymphoma, Version 2.2025","author":"Hoppe RT","unstructured":"Hoppe RT, Advani RH, Ambinder RF,  NCCN Clinical Practice Guidelines in Oncology: Hodgkin Lymphoma, Version 2.2025. Accessed July 29, 2025. To view the most recent version, visit https:\/\/www.nccn.org"},{"key":"B42","series-title":"N Engl J Med","first-page":"310","article-title":"Overall survival with brentuximab vedotin in stage III or IV Hodgkin\u2019s lymphoma","volume":"387","author":"Ansell SM","year":"2022","unstructured":"Ansell SM, Radford J, Connors JM,  Overall survival with brentuximab vedotin in stage III or IV Hodgkin\u2019s lymphoma. N Engl J Med 2022;387:310\u2013320."},{"key":"B43","series-title":"N Engl J Med","first-page":"1379","article-title":"Nivolumab+AVD in advanced-stage classic Hodgkin\u2019s lymphoma","volume":"391","author":"Herrera AF","year":"2024","unstructured":"Herrera AF, LeBlanc M, Castellino SM,  Nivolumab+AVD in advanced-stage classic Hodgkin\u2019s lymphoma. N Engl J Med 2024;391:1379\u20131389."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/24\/9\/article-e267019.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/24\/9\/article-e267019.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/24\/9\/article-e267019.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T12:53:08Z","timestamp":1789563188000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/24\/9\/article-e267019.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":43,"journal-issue":{"issue":"9"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2026.7019","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]}}}